| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
but Not p110
Promotes Optimal Allergic Responses In Vivo1
* Centre for Cell Signalling, Institute of Cancer, Queen Mary University of London, London, United Kingdom;
Geneva Research Center, Merck Serono International, Geneva, Switzerland; and
Frimorfo, Fribourg, Switzerland
The leukocyte-enriched p110
and p110
isoforms of PI3K have been shown to control in vitro degranulation of mast cells induced by cross-linking of the high affinity receptor of IgE (Fc
RI). However, the relative contribution of these PI3K isoforms in IgE-dependent allergic responses in vivo is controversial. A side-by-side comparative analysis of the role of p110 and p110 in mast cell function, using genetic approaches and newly developed isoform-selective pharmacologic inhibitors, confirms that both PI3K isoforms play an important role in FcRI-activated mast cell degranulation in vitro. In vivo, however, only p110 was found to be required for optimal IgE/Ag-dependent hypersensitivity responses in mice. These observations identify p110 as a key therapeutic target among PI3K isoforms for allergy- and mast cell-related diseases.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by the Biotechnology and Biological Science Research Council U.K. (Grant BB/C505659/1), the European Union FP6-502935, Barts and the London Charity, and the Ludwig Institute for Cancer Research.
2 Current address: Intellikine, La Jolla, CA 92037.
3 Address correspondence and reprint requests to Dr. Bart Vanhaesebroeck, Centre for Cell Signaling, Institute of Cancer, Queen Mary, University of London, Sir John Vane Research Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. E-mail address: bart.vanh{at}qmul.ac.uk
4 Abbreviations used in this paper: GPCR, G protein-coupled receptor; BMMC, bone marrow-derived mast cell; HSA, human serum albumin; i.d., intradermal; KO, knock-out; PCA, passive cutaneous anaphylaxis; SCF, stem cell factor; WT, wild type; Tyr, tyrosine; PKB, protein kinase B.
This article has been cited by other articles:
|
|
 |
|
  J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, W. Wrasidlo, et al. Aerosolized Phosphoinositide 3-Kinase {gamma}/{delta} Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 758 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Billottet, L. Banerjee, B. Vanhaesebroeck, and A. Khwaja Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation Cancer Res., February 1, 2009; 69(3): 1027 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Papakonstanti, O. Zwaenepoel, A. Bilancio, E. Burns, G. E. Nock, B. Houseman, K. Shokat, A. J. Ridley, and B. Vanhaesebroeck Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages J. Cell Sci., December 15, 2008; 121(24): 4124 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zebedin, O. Simma, C. Schuster, E. M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J. A. Schmid, et al. Leukemic challenge unmasks a requirement for PI3K{delta} in NK cell-mediated tumor surveillance Blood, December 1, 2008; 112(12): 4655 - 4664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Weichhart and M D Saemann The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii70 - iii74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Thomas, J. S. Mitchell, C. C. DeNucci, A. L. Martin, and Y. Shimizu The p110{gamma} isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites J. Leukoc. Biol., September 1, 2008; 84(3): 814 - 823. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
